Table 1.
Key recommendations on pharmacological treatment of IPF according to current guideline.
| 2015 Guideline | 2011 Guideline | |
|---|---|---|
| THERAPEUTIC AGENT | ||
| Pirfenidone | Conditional recommendation for use* | Weak recommendation against use |
| Nintedanib | Conditional recommendation for use | Not addressed |
| Antiacid therapy | Conditional recommendation for use | Weak recommendation for use |
| Phosphodiesterase-5 inhibitor (sildenafil) | Conditional recommendation against use | Not addressed |
| Dual endothelin receptor antagonists (bosentan, macitentan) | Conditional recommendation against use | Strong recommendation against use |
| N-acetylcysteine (NAC) | Conditional recommendation against use | Weak recommendation against use |
| Azathioprine + corticosteroids + NAC | Strong recommendation against use | Weak recommendation against use |
| Warfarin | Strong recommendation against use | Weak recommendation against use |
| Imatinib | Strong recommendation against use | Not addressed |
| Selective endothelin receptor antagonist (ambrisentan) | Strong recommendation against use | Not addressed |
*
Conditional recommendations are synonymous with weak recommendations